Three High-Potential Stocks Worth Your Thousand Dollars Today

The Energy Infrastructure Play: GE Vernova

The power generation landscape is undergoing a seismic shift. General Electric’s 2021 restructuring once seemed like a desperate attempt to save a declining legacy company. Yet one of its spinoffs has emerged as a genuine winner in an era demanding unprecedented electrical capacity.

GE Vernova (NYSE: GEV) manufactures industrial-scale equipment for wind, nuclear, hydro, and conventional power generation, alongside grid infrastructure and energy management software. Last year alone, the company generated $35 billion in revenue, with nearly half derived from recurring service contracts. More impressively, it booked $44 billion in new orders—a sign of ravenous demand ahead.

Why such momentum? Goldman Sachs projects that by 2030, electricity consumption will surge 165% above current levels, primarily driven by artificial intelligence data centers. While renewable energy remains the environmental preference, the transition timeline demands traditional power infrastructure fill the gap. Data center operators recognize this urgency: infrastructure provider Crusoe recently ordered 19 additional gas turbines from GE Vernova to generate power at consumption sites, bringing its total commitment to 29 units.

The company’s $135.3 billion backlog—growing faster than delivery capacity—tells the real story. This represents the best stocks to buy for those seeking exposure to structural energy demand shifts.

Semiconductor Dominance: Taiwan Semiconductor Manufacturing

The semiconductor industry faces a paradox. Competitors desperately want independence from any single supplier, yet Taiwan Semiconductor Manufacturing (NYSE: TSM) remains virtually unassailable. The company manufactures most of the world’s high-performance chips, a position fortified by staggering complexity, capital requirements, and time investments that discourage rival foundries.

Consider Intel’s retreat. The company downscaled its pandemic-era ambitions to build competing manufacturing capacity—a tacit admission that foundry competition is harder than anticipated. Even Nvidia, a major TSMC customer, understands the reality. CEO Jensen Huang stated in August that “TSMC is one of the greatest companies in the history of humanity,” essentially acknowledging the manufacturer’s unshakeable market position won’t face meaningful pressure soon.

Nvidia and Intel collaborating on AI infrastructure? Microsoft and OpenAI working together despite competitive tensions? Such partnerships reflect industry desperation for speed and capacity. Taiwan Semiconductor Manufacturing faces no such desperation—it simply manufactures what others need. Market pullbacks from recent highs present tactical entry opportunities for investors seeking best stocks to buy with long-term conviction.

The Gene-Editing Opportunity: CRISPR Therapeutics

Revolutionary science sometimes struggles with market appreciation. CRISPR Therapeutics (NASDAQ: CRSP) co-founders Emmanuelle Charpentier and Jennifer Doudna won the 2020 Nobel Prize in Chemistry for developing gene-editing technology capable of modifying human genetic code. Yet the stock has stalled since the company’s first regulatory approval in late 2023.

That approval—Casgevy for transfusion-dependent beta thalassemia—represents merely the opening chapter. The real opportunity unfolds as investors recognize that manufacturing and administering patient-specific dosing takes months between treatment initiation and revenue recognition. This manufacturing lag creates a timing disconnect between clinical progress and financial results.

Analysts expect this year’s revenue to more than quadruple next year once early Casgevy patients complete their full treatment cycles and billing follows. Additional catalysts loom: upcoming trial results for CTX112, the company’s cardiovascular and diabetes programs, could validate the broader gene-editing platform. These developments position CRISPR Therapeutics among the best stocks to buy for investors willing to endure temporary volatility while transformative therapies reach market maturity.

Finding Value in Today’s Market

With $1,000 ready for deployment, these three companies offer compelling risk-reward profiles beyond the dominant AI narrative. GE Vernova captures structural power demand growth, Taiwan Semiconductor Manufacturing remains irreplaceably dominant, and CRISPR Therapeutics approaches a critical revenue inflection point. Each represents distinct sectors experiencing genuine long-term tailwinds—precisely where disciplined investors find opportunity.